We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Scancell Holdings plc (SCLP) Ord GBP0.001

Sell:10.50p Buy:11.50p 0 Change: No change
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:10.50p
Buy:11.50p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:10.50p
Buy:11.50p
Change: No change
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. Its lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.

Contact details

Address:
Unit 202 Bellhouse Building
Sanders Road, Oxford Science Park
OXFORD
OX4 4GD
United Kingdom
Telephone:
+44 (01865) 582066
Website:
https://www.scancell.co.uk/

Important dates

Future events
There are no future events available.
Past events
AGM 25 October 2024 25/10/24
Interim results 30 January 2024 30/01/24

General stock information

EPIC:
SCLP
ISIN:
GB00B63D3314
Market cap:
£102.26 million
Shares in issue:
929.60 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Phil L'huillier
    Chief Executive Officer, Executive Director
  • Sathijeevan Nirmalananthan
    Chief Financial Officer, Executive Director
  • Lindy Durrant
    Chief Scientific Officer, Executive Director
  • Callum Scott
    Head of Development
  • Nermeen Varawalla
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.